share_log
Breakings ·  05:05

Nov 07 (Reuters) - Ventyx Biosciences Q3 Operating Expenses USD 38.552 Million.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment